(Nature Communications)
People with a previous rheumatoid arthritis diagnosis had a 30% to 50% lower risk of later developing Parkinson s, a nested case-control study showed.
(Journal of Parkinson s Disease)
(Movement Disorders)
(New York Times)
(Alzheimer s and Dementia)
Medicare data showed that payments for neurologist-prescribed brand name drugs jumped 50% from 2013 to 2017, but claims for these drugs rose only 8%. (Neurology)
(JAMA Network Open)
Military veterans with psychogenic or epileptic seizures had higher risks for death by suicide and suicide-related behavior than the general veteran population.
(Neurology Clinical Practice)
Silencing a gene involved in pain signaling reduced pain sensitivity in animal models and reversed chemotherapy-induced chronic pain in mice. (
E-Mail
The impact of the COVID-19 pandemic on public health is staggering; more than one hundred million cases and two million deaths worldwide. In response, most countries and local governments have taken substantial measures such as travel restrictions and physical distancing to keep their citizens safe. Both the pandemic and related protective measures pose challenges for ongoing clinical research studies seeking to treat and prevent the world s greatest public health emergencies including COVID-19, but also Alzheimer s disease and other dementia.
In a new paper from the World-Wide FINGERS network in Alzheimer s & Dementia: Translational Research and Clinical Interventions, first author Susanne Röhr, Ph.D., clinical psychologist at the Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Germany, and colleagues provide timely guidance on the design and management of clinical research during COVID-19 specifically on the conduct of
Discovery of early plasma biomarkers for Alzheimer s disease | Mike Cohen ‹ Cohen Chatter thesuburban.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thesuburban.com Daily Mail and Mail on Sunday newspapers.
A team of researchers at the Institut national de la recherche scientifique (INRS) team has identified two early markers in plasma that can detect Alzheimer’s disease five years before its
INRS research team composed of Professor Charles Ramassamy, specialist in Alzheimer’s disease, PhD student Mohamed Raâfet Ben Khedher and postdoctoral student Mohamed Haddad (from left to right). (Photo: Institut National de la recherche scientifique INRS)
A Quebec research team supported by the Laval-based Institut national de recherche scientifique (INRS) has discovered two early plasma markers to detect Alzheimer’s disease five years before its onset.
The results of this recent study led by the doctoral student Mohamed Raâfet Ben Khedher and postdoctoral student Mohamed Haddad, and directed by Professor Charles Ramassamy of the INRS, have just been published in the prestigious scientific journal